Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response

Cancer Immunology, Immunotherapy : CII
Naoya HashimotoHaruo Sugiyama

Abstract

To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed. Seven patients with histological diagnosis of glioblastoma underwent concurrent radiotherapy and temozolomide therapy. Patients first received Wilms tumor 1 peptide vaccination 1 week after the end of combined concurrent radio/temozolomide therapy, and administration was continued once per week for 7 weeks. Temozolomide maintenance was started and performed for up to 24 cycles, and the observation period for safety encompassed 6 weeks from the first administration of maintenance temozolomide. All patients showed good tolerability during the observation period. Skin disorders, such as grade 1/2 injection-site reactions, were observed in all seven patients. Although grade 3 lymphocytopenia potentially due to concurrent radio/temozolomide therapy was observed in five patients (71.4 %), no other grade 3/4 hematological or neurological toxicities were observed. No autoimmune reactions were observed. All patients are still alive, and six are on Wilms tumor 1 peptide vaccination without progression, yielding a progression-free survival from histological diagnosis of 5.2-49.1 months....Continue Reading

References

Feb 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·Y OkaH Sugiyama
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppSerge Leyvraz
Aug 22, 2002·Current Cancer Drug Targets·Y OkaH Sugiyama
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y B SuPaul B Chapman
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama
Oct 27, 2004·Cancer Science·Yusuke OjiHaruo Sugiyama
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryuya YamanakaRyuichi Tanaka
May 25, 2007·Cancer Immunology, Immunotherapy : CII·Justin T JordanAmy B Heimberger
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antje WickWolfgang Wick
Feb 18, 2009·Cancer Immunology, Immunotherapy : CII·Claire BanissiAntoine F Carpentier
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin A CheeverLynn M Matrisian
Oct 3, 2009·Acta Neuropathologica·David CapperAndreas von Deimling
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R PerryJean-François Pouliot
Apr 7, 2010·Japanese Journal of Clinical Oncology·Yasuyoshi ChibaToshiki Yoshimine
Sep 30, 2010·Journal of Neuro-oncology·Ufuk AbaciogluMeric Sengoz
Oct 5, 2010·International Journal of Radiation Oncology, Biology, Physics·Jing LiMinesh P Mehta
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Nov 11, 2010·Nucleic Acids Research·Faviel F Gonzalez-GalarzaAndrew R Jones
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mizuhiko TerasakiKyogo Itoh
Aug 3, 2011·International Journal of Clinical Oncology·Yasunori FujimotoToshiki Yoshimine
Mar 23, 2013·Neuro-oncology·Hiroyuki MomotaSoichiro Shibui

❮ Previous
Next ❯

Citations

Apr 2, 2016·Bulletin du cancer·Antoine SchernbergFrédéric Dhermain
Apr 19, 2016·Neurologia Medico-chirurgica·Naoya Hashimoto
Apr 9, 2016·Oncoimmunology·David C BinderDerek A Wainwright
Jan 13, 2018·International Journal of Cancer. Journal International Du Cancer·Yusuke OjiHaruo Sugiyama
May 19, 2019·Current Oncology Reports·Ding Fang Chuang, Xuling Lin
Sep 25, 2015·Current Opinion in Neurology·Tobias WeissPatrick Roth
Dec 23, 2016·Frontiers in Oncology·Valérie DutoitPaul R Walker
Apr 9, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Visish M SrinivasanAmy B Heimberger
Jan 30, 2021·Journal of Immunotherapy·Thi-Anh-Thuy TranTae-Young Jung
May 13, 2021·Brain Tumor Pathology·Eiichi IshikawaHiroyoshi Akutsu
Jul 18, 2021·Cancer Immunology, Immunotherapy : CII·Hiroko NakajimaHaruo Sugiyama
Oct 26, 2021·Frontiers in Bioengineering and Biotechnology·Kai MengXiaomei Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.